rate of recurrence, particularly distant recurrence, by approximately 50 percent" 1 and "The addition of trastuzumab to paclitaxel after a regimen of doxorubicin and cyclophosphamide reduced the rates of recurrence by half among women with HER2-positive breast cancer." 2 Dr. Nash's letter calls attention to the importance of understanding the difference between absolute and relative risks in analyzing the results of clinical trials.
No takes yet. Share an insight, caveat, or question.
Young et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: